Dicerna Pharmaceuticals Inc

No Longer Reporting

The company has not filed an annual or quarterly report since its Q3 FY2021 10-Q, filed Nov 9, 2021. Its latest SEC filing is a SC 13G/A from Feb 14, 2022.

The sections below describe the company as of the FY2020 annual report.

What Did They Do?

Develops RNAi-based medicines that silence disease-causing genes for patients with rare and more prevalent diseases, and works with pharmaceutical companies on drug programs.

How Did They Make Money?

Pharmaceutical partners pay for technology licenses and research or development work, with money arriving upfront or as services are provided. Dicerna can also receive option and milestone payments, plus royalties when licensed products sell.

Who Were Their Customers?

Pharmaceutical companies work with Dicerna on discovery and development programs. If a product is approved, Dicerna plans to market it directly or through strategic alliances or distribution agreements.

Did Revenues Turn Into Profits?

Not on paper. It lost $112.7M in FY2020, but brought in more cash than it spent: $163.4M of free cash flow.

How Were They Changing?

Grew. Revenue grew 557.0x in 4 years, from $295K in FY2016 to $164.3M in FY2020, about 386% a year.

Who Did They Compete With?

Competes with Oxthera, Allena Pharmaceuticals, Arbutus Biopharma, Vir Biotechnology, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Quark Pharmaceuticals, Avidity Biosciences, Ionis Pharmaceuticals, Dyne Therapeutics, Wave Life Sciences, Biocodex, Adial Pharmaceuticals, and Amygdala Neurosciences